Evidence map›Paper›PMID 33104403›Full record

ArticleCirculation2020

Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism".

Nicholas A Marston, Christian T Ruff, Marc S Sabatine

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Nicholas A MarstonTIMI Study Group, Division of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Christian T RuffTIMI Study Group, Division of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Marc S SabatineTIMI Study Group, Division of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Funding

Discovery and Application of Germline and Somatic Mutations for Risk Prediction and Personalized Therapy to Prevent Recurrent Myocardial InfarctionK08HL153950 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MARSTON, NICHOLAS · 2020 to 2024
$647k
Creating Genetic Risk Scores to Predict Secondary Coronary Events, Response to Ezetimibe Therapy, and Development of Diabetes after Acute Coronary SyndromeF32HL144029 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MARSTON, NICHOLAS · 2018 to 2019
$172k
NHLBI NIH HHS F32 HL144029NHLBI NIH HHS K08 HL153950NHLBI NIH HHS L30 HL143770
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Proprotein Convertase 9Venous ThromboembolismCholesterol, LDLHumansSubtilisinsCholesterol, LDLPCSK9 protein, humanProprotein Convertase 9Subtilisins

Identifiers

PMID33104403
PMCPMC7641032

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.